Trial · NCT05356611
Engage for Late-Life Depression and Comorbid Executive Dysfunction
NCT05356611, Not applicable, Unknown, University of Nevada, Las Vegas
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Engage for Late-Life Depression and Comorbid Executive Dysfunction. Trials, record NCT05356611. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05356611
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Engage for Late-Life Depression and Comorbid Executive Dysfunction
- NCT number
- NCT05356611
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- University of Nevada, Las Vegas
- Conditions
- Depression in Old Age, Psychotherapy, Mild Cognitive Impairment, Executive Dysfunction
- Interventions
- Engage
- First posted
- 2022-05-02
- Last updated
- 2024-08-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hamilton Depression Rating Scale | Assessed at Baseline, Week 6, Week 9, and Week 36 follow-up. | Measure of depressive symptoms used to assess changes across treatment from baseline to mid-treatment, to post-treatment, and follow up at 36 weeks post-baseline. Scores range from 0 - 54 with higher scores indicating worse depression. |
| Secondary | World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) | Assessed at Baseline, Week 6, Week 9, and Week 36 follow-up. | Measure of disability and functioning. Scores range from 0 to 100, with higher scores indicating worse disability. |
| Secondary | Behavioral Activation for Depression Scale (BADS) | Assessed at Baseline, Week 6, Week 9, and Week 36 follow-up. | Measure of behavioral activation (target mechanism). Scores range from 0 to 54, with higher scores indicating more dysfunction. |
| Secondary | Social Problem-Solving Inventory Revised-Short Form | Assessed at Baseline, Week 6, Week 9, and Week 36 follow-up. | measure of problem solving skills. Total scores range from 0 to 100. When all appropriate items are reverse-scored, higher scores indicate better social problem solving functioning. |
| Other | Iowa Gambling Task - 2nd Edition | Baseline, Week 9, and Week 36 follow-up. | Measure of reward response, decision-making and problem solving. Assess changes in target executive functioning skills across treatment. Produces multiple scores, generally with higher scores indicating better decision making. |
| Other | Hopkins Verbal Learning Memory Test-Revised | Baseline, Week 9, and Week 36 follow-up. | Measure of memory. Assess potential changes in memory functioning across treatment. Consists of multiple trials and multiple ranges, with higher scores on each trial indicating better memory. |
| Other | Stroop Color-Word Interference Test | Baseline, Week 9, and Week 36 follow-up. | Measure of processing speed and response inhibition. Assess changes in target executive functioning skills across treatment. Produces multiple scores across multiple trials and ranges, with higher scores indicating better performance. |
| Other | Trail Making Test A & B | Baseline, Week 9, and Week 36 follow-up. | Measure of processing speed and set-shifting. Assess changes in target executive functioning skills across treatment. Time limited task, with higher time indicating worse performance. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Iowa Gambling Lite | Other outcome | ConductCognition |
| Stroop Color-Word Test | Other outcome | ConductCognition |
| Trail Making Test A | Other outcome | ConductCognition |
| Trail Making Test B | Other outcome | ConductCognition |
| Verbal Learning | Other outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05356611
GET https://conductscience.org/api/trials/v1/NCT05356611/registered